Patent application number | Description | Published |
20110144362 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME - The invention relates to anhydrides, solvates and ethanol hetero-solvates and hydrates of dimethoxy docetaxel or (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β, 10β-dimethoxy-9-oxo-tax-11-ene-13α-yl, and to the preparation thereof. | 06-16-2011 |
20130178639 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME - The invention relates to anhydrides, solvates and ethanol hetero-solvates and hydrates of dimethoxy docetaxel or (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β, 10β-dimethoxy-9-oxo-tax-11-ene-13α-yle, and to the preparation thereof. | 07-11-2013 |
20140350272 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME - The invention relates to anhydrides, solvates and ethanol hetero-solvates and hydrates of dimethoxy docetaxel or (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β, 10β-dimethoxy-9-oxo-tax-11-ene-13α-yle, and to the preparation thereof. | 11-27-2014 |
Patent application number | Description | Published |
20110152311 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 06-23-2011 |
20130267480 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 10-10-2013 |
20140349967 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 11-27-2014 |
20150246920 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 09-03-2015 |
Patent application number | Description | Published |
20090197344 | METHOD FOR THE PREDICTION OF VASCULAR EVENTS AND THE DIAGNOSIS OF ACUTE CORONARY SYNDROME - The present invention relates to a method for the prognosis of a vascular event or the diagnosis of ACS in a patient suspected of being at risk for a vascular event or condition, said patient presenting:
| 08-06-2009 |
20100209939 | BNP(1-32) EPITOPE AND ANTIBODIES DIRECTED AGAINST SAID EPITOPE - The present invention relates to a polypeptide carrying a human BNP(I-32) epitope according to Formula (I): a | 08-19-2010 |
20110312517 | METHOD FOR THE IN VITRO DIAGNOSIS OF STROKE - The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps:
| 12-22-2011 |
20120028824 | METHOD FOR THE IN VITRO DIAGNOSIS OF STROKE - A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1-108), or of fragments of proBNP(1-108), and the level of NDKA, with one or several cut-off values; and (d) determining therefrom whether a stroke or a TIA has occurred in the individual. | 02-02-2012 |
Patent application number | Description | Published |
20140105977 | GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS - The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. | 04-17-2014 |
20140170217 | COMBINATION COMPOSITION COMPRISING OXYCODONE AND ACETAMINOPHEN FOR RAPID ONSET AND EXTENDED DURATION OF ANALGESIA - The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof. | 06-19-2014 |
20140288113 | Extended Release Compositions Comprising Hydrocodone And Acetaminophen For Rapid Onset And Prolonged Analgesia That May Be Administered Without Regard To Food - The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof. | 09-25-2014 |
20140294956 | GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS - The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. | 10-02-2014 |
20140378498 | Tamper Resistant Composition Comprising Hydrocodone And Acetaminophen For Rapid Onset And Extended Duration Of Analgesia - The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof. | 12-25-2014 |
20150246034 | PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF OXYCODONE AND ACETAMINOPHEN RESULTING IN A QUICK ONSET AND PROLONGED PERIOD OF ANALGESIA - The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subject's body faster than it is being absorbed. | 09-03-2015 |
Patent application number | Description | Published |
20130179942 | CONSOLIDATED DATA SERVICES APPARATUS AND METHOD - An apparatus for consolidated data services comprising a plurality of devices, a plurality of data services and a content application programming interface (API). A user API provides user identification for each of the plurality of devices using one or more of a plurality of user API methods. A feedback API configured to receive data from each of the plurality of devices that identifies media content that was delivered to the plurality of devices using one or more of a plurality of feedback API methods. A device API configured to provide a client system to one or more of the plurality of devices using one or more of a plurality of device API methods. A web service consolidator coupled to the content API, the user API, the feedback API, the device API, the update API, a plurality of data services and the plurality of devices through the communications media. | 07-11-2013 |
20140059572 | CONSOLIDATED DATA SERVICES APPARATUS AND METHOD - An apparatus for consolidated data services comprising a plurality of devices, a plurality of data services and a content application programming interface (API). A user API provides user identification for each of the plurality of devices using one or more of a plurality of user API methods. A feedback API configured to receive data from each of the plurality of devices that identifies media content that was delivered to the plurality of devices using one or more of a plurality of feedback API methods. A device API configured to provide a client system to one or more of the plurality of devices using one or more of a plurality of device API methods. A web service consolidator coupled to the content API, the user API, the feedback API, the device API, the update API, a plurality of data services and the plurality of devices through the communications media. | 02-27-2014 |